Pfizer/BioNTech COVID-19 vaccine produces strong immune response in children

Pfizer and BioNTech have announced recent data from a top-line safety, immunogenicity and vaccine efficacy phase 2/3 trial assessing a third 3µg dose – one-tenth of the adult dosage – of their COVID-19 vaccine for children aged from six months to under five years old. The vaccine resulted in a strong immune response following the third dose in this particular age group, and showed a positive safety profile similar to placebo. One of the second endpoints in the trial was vaccine efficacy, which was 80.3% in children aged six months to under five years. This analysis was taken during a period when the Omicron strain was the predominant variant, and was based on ten symptomatic COVID-19 cases identified seven days after the third dose and accrued as of 29 April 2022.